Sun Pharmaceutical Industries Ltd. today announced the expiration of the Tender Offer by Sun’s subsidiary, Alkaloida Chemical Company Exclusive Group Ltd., to purchase all outstanding Ordinary Shares of Taro Pharmaceutical Industries Ltd. for $7.75 per Ordinary Share.
“Sun is pleased to be able to finally close the Offer,” said Dilip Shanghvi, Chairman and Managing Director of Sun. Transactions contained in an Option Agreement related to the transfer of Taro shares owned or controlled by the Levitts to Sun and its affiliates are to be consummated contemporaneously with the expiration of the Offer. “We will now make every effort to consummate our Option Agreement to purchase the Levitts’ controlling shares of Taro,” he added.
Sun has been informed by Computershare, the Depositary for the Offer, that as of the expiration of the Offer at midnight, New York City time, on September 14, 2010, a total of 29,382 Ordinary Shares, or approximately 0.07% of Taro’s outstanding Ordinary Shares, had been tendered into the Offer and not withdrawn. No Ordinary Shares were tendered subject to guaranteed delivery. All Ordinary Shares validly tendered and not properly withdrawn prior to the expiration of the Offer have been accepted and Alkaloida will pay for such Ordinary Shares promptly.
As of 9:00 a.m., New York City time, on September 15, 2010, Alkaloida commenced a subsequent offering period for all remaining Ordinary Shares that have not yet been tendered. Stockholders who tender Ordinary Shares during such period will be paid the same $7.75 per Ordinary Share, net to the seller in cash (subject to applicable withholding taxes), paid during the Offer. Ordinary Shares tendered during the subsequent offering period may not be withdrawn. Alkaloida will immediately accept any Ordinary Shares validly tendered during the subsequent offering period as they are tendered, and will pay for such Ordinary Shares promptly. The subsequent offering period will expire at 12:00 midnight, New York City time, on Tuesday, September 28, 2010.